RxDoctor Payments DataLook up a doctor →

Sait Ashina, MD

Neurology · New York, NYNPI 1194042895

Payments from drug & device makers

$840,042in general payments, 2019–2025

Across 405 payments — averaging $2074.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$413K
  • AbbVie$228K
  • Eli Lilly$66K
  • Pfizer$40K
  • Lilly USA, LLC$32K
  • H. Lundbeck A S$29K
  • plus $31K from 11 others

What the payments were for

  • Consulting fees$156,04357%
  • Speaking & faculty fees$48,67518%
  • Travel & lodging$56,87921%
  • Food & beverage$10,1384%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$840,042 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$39,527
Medicare patients
131
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate65$100,106
Emgality PenGalcanezumab-Gnlm66$51,987
UbrelvyUbrogepant34$43,773
Ajovy AutoinjectorFremanezumab-Vfrm44$34,808
QuliptaAtogepant23$30,580
Aimovig AutoinjectorErenumab-Aooe33$25,334
Emgality SyringeGalcanezumab-Gnlm12$13,349
Eletriptan HbrEletriptan Hydrobromide17$1,080
Naratriptan Hcl24$971
Topiramate33$935
Sumatriptan Succinate63$475
RizatriptanRizatriptan Benzoate29$256
Gabapentin13$158
Nortriptyline Hcl12$155
Lamotrigine12$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$39,664$100,10665 claims
AbbVieUbrelvy, Qulipta$228,298$74,35357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →